ID   CSQT-2
AC   CVCL_M183
DR   CCRID; 4201PAT-CCTCC00280
DR   Wikidata; Q54814674
RX   Patent=CN101955914B;
RX   PubMed=20461085;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200913.
CC   Population: Chinese.
CC   Doubling time: 36 hours (Patent=CN101955914B).
CC   Derived from site: Metastatic; Portal vein; UBERON=UBERON_0002017.
DI   NCIt; C7956; Adult hepatocellular carcinoma
DI   ORDO; Orphanet_210159; Adult hepatocellular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   60Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 29-06-23; Version: 12
//
RX   Patent=CN101955914B;
RA   Wu M.-C., Wang T., Cheng J.-Y., Cheng S.-Q., Hu H.-S., Xie D.;
RT   "Human hepatocellular carcinoma cell line with portal vein transfer
RT   potential.";
RL   Patent number CN101955914B, 23-May-2012.
//
RX   PubMed=20461085; DOI=10.1038/sj.bjc.6605689;
RA   Wang T., Hu H.-S., Feng Y.-X., Shi J., Li N., Guo W.-X., Xue J.,
RA   Xie D., Liu S.-R., Wu M.-C., Cheng S.-Q.;
RT   "Characterisation of a novel cell line (CSQT-2) with high metastatic
RT   activity derived from portal vein tumour thrombus of hepatocellular
RT   carcinoma.";
RL   Br. J. Cancer 102:1618-1626(2010).
//